Lipids in Health and Disease最新文献

{"title":"Association between remnant cholesterol (RC) and endometriosis: a cross-sectional study based on NHANES data.","authors":"Zeru Chen, Ruixuan Li, Jiajie Guo, Xiaorong Ye, Yang Zhou, Mingzhu Cao","doi":"10.1186/s12944-024-02422-4","DOIUrl":"10.1186/s12944-024-02422-4","url":null,"abstract":"<p><strong>Background: </strong>Prior research indicates a potential link between dyslipidemia and endometriosis (EMs). However, the relationship between remnant cholesterol (RC) and EMs has not been thoroughly investigated. Consequently, looking into and clarifying the connection between RC and EMs was the primary goal of this study.</p><p><strong>Methods: </strong>Following the screening of participants from the NHANES dataset spanning 2001 to 2006, a total of 1,840 individuals were incorporated into this research. A weighted multivariable logistic regression analysis was first performed to investigate the relation between RC and the likelihood of encountering EMs. To assess the degree of consistency in the link between RC and EMs across different populations, additional subgroup analyses were performed. In addition, the researchers used the extreme gradient boosting (XGBoost) technique and the area under the receiver operating characteristic curve (ROC) to evaluate how well RC recognized EMs. Lastly, both linear and nonlinear relationships were validated using generalized additive models (GAM), while dose-response connections were investigated through restricted cubic spline models.</p><p><strong>Results: </strong>After accounting for all potential confounders, a strong correlation between RC and EMs was identified. In particular, an increase of one unit in RC was linked to a 135% rise in the likelihood of developing EMs. Analyses of subgroups revealed that these relationships remained stable across the majority of subgroups (interaction P-value > 0.05). Multivariable logistic regression demonstrated RC's independent predictive value, maintaining statistical significance after adjusting for confounders. The AUC of 0.614 suggests RC's moderate ability to discriminate EMs, outperforming traditional markers like LDL-C in sensitivity and specificity. Furthermore, XGBoost analysis identified RC as the most critical predictor among lipid-related and demographic variables. The relationship was further validated through GAM, which visually confirmed a linear trend, and RCS, which provided statistical evidence of linearity.</p><p><strong>Conclusion: </strong>This study reveals a clear connection between RC and the likelihood of having EMs within the US population, suggesting RC as a potential marker for further investigation in understanding endometriosis risk.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"2"},"PeriodicalIF":3.9,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of the gut bacterial product, gassericin A, on obesity in mice.","authors":"Valeh Mahdavi, Hamid Reza Kazerani, Fereidoun Taghizad, Hedyeh Balaei","doi":"10.1186/s12944-024-02423-3","DOIUrl":"10.1186/s12944-024-02423-3","url":null,"abstract":"<p><strong>Background: </strong>Obesity can arise from various physiological disorders. This research examined the impacts of the bacteriocin, gassericin A, which is generated by certain gut bacteria, using an in vivo model of obesity.</p><p><strong>Methods: </strong>Fifty Swiss NIH mice were randomly assigned to five different groups. One group was given a standard diet, while the remaining groups were fed a diet high in fat and sugar. The test groups received gassericin A at doses of 0.75, 1.5, or 3 mIU/kg through intraperitoneal injection, daily for 10 weeks. Body weight, fasting blood sugar, serum lipid profile, and hepatic function indicators were then assessed. Additionally, the blood profile, markers of oxidative stress, and expression levels of specific genes associated with obesity, Zfp423, and Fabp4, were evaluated in abdominal adipose tissue.</p><p><strong>Results: </strong>A high-calorie diet negatively impacted abdominal fat, serum cholesterol, LDL, and hepatic enzymes. However, gassericin A significantly improved these effects, despite increasing weight gain and abdominal fat. Furthermore, it improved redox status, downregulated the Zfp423 gene, and enhanced the expression of the Fabp4 gene. Finally, the bacteriocin caused thrombocytopenia and mild decreases in erythrocytes, hematocrit, and hemoglobin levels.</p><p><strong>Conclusions: </strong>These results suggest that, despite causing weight gain, gassericin A may improve obesity-related complications.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"3"},"PeriodicalIF":3.9,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142927460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FTO rs1121980 polymorphism contributes to coronary artery disease susceptibility in a Chinese Han population.","authors":"Xue Min, Yu-Lan Zhou, Yun-Fei Qu, Zhao-Fu Liao, Heng Li, Jie Cheng, Li-Li Liang, Hai-Liang Mo, Zhu-Guo Wu, Xing-Dong Xiong","doi":"10.1186/s12944-024-02417-1","DOIUrl":"10.1186/s12944-024-02417-1","url":null,"abstract":"<p><strong>Background: </strong>The fat mass and obesity-associated protein (FTO) has been showed to be involved in the pathogenesis and progression of coronary artery disease (CAD). However, the effects of FTO variants on CAD risk remain poorly understood. We herein genotyped three SNPs (rs1121980, rs72803657, and rs4783818) in FTO to investigate the influence of FTO polymorphisms on individual susceptibility to CAD.</p><p><strong>Methods: </strong>Genotyping for the three SNPs (rs1121980, rs72803657, and rs4783818) was conducted in a cohort of 712 CAD cases with 349 myocardial infarction (MI) cases and 701 control participants, utilizing the polymerase chain reaction-ligation detection reaction (PCR-LDR) technique. The associations of these SNPs with CAD were analyzed using multivariate logistic regression, and the associations with lipid profiles were assessed by the Kruskal-Wallis or Wilcoxon-Mann-Whitney tests.</p><p><strong>Results: </strong>The A allele (OR = 1.26, 95% CI = 1.01-1.57, and P = 0.044) and the AA genotype (OR = 3.13, 95% CI = 1.53-6.38, and P = 0.002) of FTO rs1121980 were significantly associated with an elevated risk of CAD. Similarly, the A allele (OR = 1.54, 95% CI = 1.18-2.02, and P = 0.002) and the AA genotype (OR = 5.61, 95% CI = 2.57-12.27, and P < 0.001) of rs1121980 exhibited increased MI risk. This SNP also showed significant associations under recessive genetic models for both CAD and MI (OR = 3.09, 95% CI = 1.52-6.27, P = 0.002 for CAD; OR = 5.40, 95% CI = 2.49-11.71, P < 0.001 for MI). However, the other two SNPs did not show significant associations with CAD or MI risks under any genetic model tested. Stratified analyses indicated a more pronounced association of the A allele with increased CAD/MI risk among younger participants, non-smokers, and non-drinkers. Interestingly, A allele carriers in younger subjects exhibited higher triglyceride (TG) levels and lower high-density lipoprotein cholesterol (HDL-C) levels compared to non-carriers (P < 0.05).</p><p><strong>Conclusions: </strong>Our data provides the first evidence that the FTO rs1121980 polymorphism is associated with an increased risk of CAD in the Chinese population. This association is more significant in younger subjects, likely due to the elevated TG levels and reduced HDL-C levels.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"24 1","pages":"1"},"PeriodicalIF":3.9,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender-specific correlations between serum lipid profiles and intra-pancreatic fat deposition: a cross-sectional study.","authors":"Ting Ran, Yanni Wang, Fengxi Yuan, Ruoyi Liu, Meng Ye, Miao Zhang, Xia Du, Jing Zheng","doi":"10.1186/s12944-024-02355-y","DOIUrl":"10.1186/s12944-024-02355-y","url":null,"abstract":"<p><strong>Background: </strong>Intra-pancreatic fat deposition (IPFD) is linked to metabolic and pancreatic diseases. MRI, while precise, is not cost-effective for routine IPFD screening, highlighting the need for accessible biomarkers. This study aims to analyze the relationships among serum lipid profiles, lipoprotein ratios, and IPFD, with a focus on sex differences.</p><p><strong>Methods: </strong>Data from adults at the Affiliated Hospital of Guizhou Medical University between 2018 and 2019 were analyzed. The subjects underwent routine Siemens 64-slice spiral CT scans, and IPFD was quantified via a quantitative computed tomography post-processing station. Lipid panel components were analyzed in the fasted state. Linear regression models stratified by gender were applied to evaluate these associations.</p><p><strong>Results: </strong>The study included 1,046 participants after exclusions, with significant sex differences found in the correlations between serum lipids, lipoprotein ratios, and IPFD. In females, remnant cholesterol was strongly associated with total IPFD (R2 = 0.155, P < 0.001), and similarly strong correlations existed with fat deposition in the pancreatic head (R² = 0.124, P = 0.003), body (R² = 0.102, P = 0.001), and tail (R² = 0.146, P = 0.005). Total cholesterol was also positively correlated with IPFD in females, particularly with the total IPFD (R² = 0.145, P = 0.002) and IPFD in the pancreatic head (R² = 0.177, P = 0.003) and body (R² = 0.100, P = 0.001). In males, triglycerides were notably correlated with IPFD in the tail (R² = 0.200, P = 0.045), but not in other regions. Similarly, total cholesterol was correlated with IPFD in the tail (R² = 0.197, P = 0.041). Additionally, in males, the triglyceride/high-density lipoprotein cholesterol ratio showed a positive association with tail fat deposition (R² = 0.200, P = 0.033).</p><p><strong>Conclusion: </strong>Significant differences between genders were evident in the correlations of serum lipids and lipoprotein ratios with IPFD. In women, remnant cholesterol was strongly correlated with IPFD, suggesting its potential as a biomarker.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"384"},"PeriodicalIF":3.9,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic index and mortality risks: elevated cancer and reduced cardiovascular mortality risk in a large cohort.","authors":"Junjie Wang, Li Xiao, Zhou Li","doi":"10.1186/s12944-024-02415-3","DOIUrl":"10.1186/s12944-024-02415-3","url":null,"abstract":"<p><strong>Background: </strong>With metabolic disorders on the rise globally, the cardiometabolic index (CMI) has emerged as a crucial predictor of mortality risks linked to cancer, cardiovascular disease, and diabetes. This novel index, which combines lipid metabolism and body composition, is the focus of this study, aimed at exploring its association with all-cause and specific mortality in an all-age adult population.</p><p><strong>Methods: </strong>A longitudinal cohort study including 5,728 participants aged over 18 from nine cycles between 2001 and 2018 was enrolled and assessed. CMI served as the exposure variable, while outcomes included all-cause mortality and mortality due to cardiovascular disease, cancer, and diabetes. The Cox frailty model and average marginal effects were employed to evaluate the contribution of CMI to all-cause and specific mortality collectively. Restricted cubic spline analyses and stratified analyses were conducted to investigate potential nonlinear effects and interactions.</p><p><strong>Results: </strong>The decreased participants exhibited considerably higher CMI than the alive's. A positive association was found between CMI and all-cause mortality (HR=1.05, 95% CI=1.01-1.10). Notably, CMI was linked to an increased risk of cancer mortality (HR=1.02) and a reduced risk of cardiovascular disease mortality (HR=0.85). Furthermore, the average marginal effect of CMI on diabetes mortality was the largest (AME=0.499). The RCS curves revealed that participants had the lowest risk of all-cause mortality at a CMI of 0.618. Sensitivity analyses further supported these findings.</p><p><strong>Conclusion: </strong>This study represents the first comprehensive assessment on the contribution of CMI to mortality across an all-age adult population, providing some insights for the comprehensive assessment of health and disease states.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"427"},"PeriodicalIF":3.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1 study of AYP-101 (soybean phosphatidylcholine): safety, pharmacokinetics, and lipid profile effects for reducing submental fat.","authors":"Hyun Joon Lee, Xu Jiang, A M Abd El-Aty, Ji Hoon Jeong, Jae-Yong Chung","doi":"10.1186/s12944-024-02387-4","DOIUrl":"10.1186/s12944-024-02387-4","url":null,"abstract":"<p><strong>Background: </strong>Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.</p><p><strong>Methods: </strong>This study was a randomized, double-blind, placebo-controlled, single-dose, two-cohort trial. Participants were randomized into groups receiving 250 mg of AYP-101, 500 mg of AYP-101, or placebo at a 9:9:8 ratio across both cohorts. Safety was assessed through standard clinical evaluations. Blood samples were collected up to 144 h postdose in cohort 1 and up to 48 h postdose in cohort 2. The PK parameters were calculated via noncompartmental analysis.</p><p><strong>Results: </strong>All 26 randomized subjects completed the study. A total of 72 solicited adverse drug reactions (ADRs) were reported by 24 subjects, all of which were mild. The most common ADRs were injection site pain and bruising. There were 29 ADR cases in the 250 mg group; 26 cases in the 500 mg group; and 18 cases in the placebo group, indicating that there were no clinically significant differences in the safety profiles between the groups. All the dose groups presented similar PK profiles, with C_max values of 12.86, 13.44, and 13.61 µg/L and AUC_0-24 h values of 278.06, 274.79, and 267.63 µg*h/L, respectively. No clinically significant differences in PK or lipid profiles were observed between the postdose group and the baseline group for any of the dose groups.</p><p><strong>Conclusions: </strong>AYP-101 appears to be a safe candidate for treating submental fat, with localized reactions and no systemic exposure at single subcutaneous doses of up to 500 mg.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05476094.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"426"},"PeriodicalIF":3.9,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial hypercholesterolemia in Chinese children and adolescents: a multicenter study.","authors":"Meng-Na Huang, Chen-Cen Wang, Ming-Sheng Ma, Mei-Zhu Chi, Qing Zhou, Li-Hong Jiang, Chun-Lin Wang, Mei Lu, Xiao-Quan Chen, Ya-Ying Cheng, Qing Ke, Da-Yan Wang, Xiao-Xia Qian, Xiao-Ming Ying, Jian-Ping Zhang, Qun-Hua Shen, Li-Fang Liu, Rui Gu, Zhen-Jie Zhang, Jian-Hua Feng, Min Wang, Ming-Qiang Zhu, Ke Huang, Jun-Fen Fu, Chao-Chun Zou","doi":"10.1186/s12944-024-02406-4","DOIUrl":"10.1186/s12944-024-02406-4","url":null,"abstract":"<p><strong>Background: </strong>Familial hypercholesterolemia (FH) is an inherited disorder mainly marked by increased low-density lipoprotein cholesterol (LDL-C) concentrations and a heightened risk of early-onset arteriosclerotic cardiovascular disease (ASCVD). This study seeks to characterize the genetic spectrum and genotype‒phenotype correlations of FH in Chinese pediatric individuals.</p><p><strong>Methods: </strong>Data were gathered from individuals diagnosed with FH either clinically or genetically at multiple hospitals across mainland China from January 2016 to June 2024.</p><p><strong>Results: </strong>In total, 140 children and adolescents (mean age of 6.00 years) with clinically and genetically diagnosed FH were enrolled in the study, with 87 distinct variants identified in the LDLR, APOB and PCSK9 genes. Among the variants, 11 variants were newly identified worldwide, with 9 classified as \"pathogenic\" or \"likely pathogenic\", and 2 classified as \"variants of uncertain significance\". Additionally, the 5 most common variants in the study were c.1448G > A (p.W483*), c.1879G > A (p.A627T), c.1216C > A (p.R406R), and c.1747C > T (p.H583Y) in the LDLR gene, as well as c.10579C > T (p.R3527W) in the APOB gene, accounting for 49.29% (69/140) of all patients. These variants are primarily observed in the Asian or Chinese population and are distinct from those present in Caucasian groups. In this cohort, 105 patients were diagnosed with heterozygous FH (HeFH), while 35 were diagnosed with homozygous FH (HoFH). Finally, only 28.57% of the patients (40/140) were using lipid-lowering medications with 33.33% of HoFH patients initiating treatment after the age of 8. Additionally, only 3 compound heterozygous patients (2.14%) underwent liver transplantation because of significantly high lipid levels.</p><p><strong>Conclusion: </strong>This study reveals the variable genotypes and phenotypes of children with FH in China and illustrates that the genotypes in the Chinese population differ from those in Caucasians, providing a valuable dataset for the clinical genetic screening of FH in China. Furthermore, the older age at diagnosis and treatment highlights the underdiagnosis and undertreatment of Chinese FH pediatric patients, suggesting that early identification should be improved through lipid or genetic screening, and that more timely and regular pharmacological treatments should be implemented.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"423"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population.","authors":"Yan-Fei Lai, Zhong-E Liang, Chun-Xiang Wu, Min Zhang, Zong-Hu Shi, Xiao-Yan Meng, Chun-Xiao Liu","doi":"10.1186/s12944-024-02407-3","DOIUrl":"10.1186/s12944-024-02407-3","url":null,"abstract":"<p><strong>Background: </strong>Lipid metabolism is influenced by mutations in the EH domain binding protein 1 gene (EHBP1). This study investigated the link between the EHBP1 single-nucleotide polymorphisms (SNPs) and dyslipidemia risks in maintenance dialysis patients with end-stage renal disease in Chinese Han population.</p><p><strong>Methods: </strong>A total of 539 patients were divided into dyslipidemia (379) and control (160) groups. The patients with dyslipidemia were divided into four subgroups: high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol (HDLC), high triglyceride (TG) and high total cholesterol groups. The genotype distributions of three EHBP1 SNPs (rs2710642, rs10496099 and rs1168816) were determined by high-throughput sequencing technology and were analyzed via generalized multifactor dimension reduction and binary logistic regression analysis.</p><p><strong>Results: </strong>The high-TG and control groups differed in terms of the genotype frequency of the rs2710642. One haplotype was detected in both the dyslipidemia and high-TG groups. The risk of dyslipidemia was 2.72-fold higher in participants with rs2710642GG compared with those of rs2710642AA and 2.62-fold higher compared with those with rs2710642AA + GA. Subjects who carried rs2710642GG had a 2.94 times greater risk of high TG levels than those who carried rs2710642AA and a 2.89 times greater risk than those who carried rs2710642AA + GA. Compared with those who carried rs2710642AA + GA, those who carried rs2710642GG were 2.53 times more likely to have low HDLC levels. The rs2710642-body mass index (BMI) (≥ 24 kg/m²) and rs11688816A-rs2710642G haplotype interactions increased the risk of dyslipidemia, and the rs2710642-BMI (≥ 24 kg/m²) interaction increased the risk of high TG levels. The rs10496099-rs2710642 and rs10496099-rs2710642-rs11688816 interactions increased the risk of low HDLC levels.</p><p><strong>Conclusions: </strong>These results suggest that the EHBP1 rs2710642G and rs2710642GG and interactions with rs11688816A or BMI (≥ 24 kg/m²) were linked to higher dyslipidemia risks in end-stage renal disease patients in Chinese Han population.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"422"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between cardiometabolic index and all-cause and cause-specific mortality among the general population: NHANES 1999-2018.","authors":"Mingjie Liu, Chendong Wang, Rundong Liu, Yan Wang, Bai Wei","doi":"10.1186/s12944-024-02408-2","DOIUrl":"10.1186/s12944-024-02408-2","url":null,"abstract":"<p><strong>Background: </strong>Cardiometabolic index (CMI) is a comprehensive clinical parameter which integrates overweight and abnormal lipid metabolism. However, its relationship with all-cause, cardiovascular disease (CVD), and cancer mortality is still obscure. Thus, a large-scale cohort study was conducted to illustrate the causal relation between CMI and CVD, cancer, and all-cause mortality among the common American population.</p><p><strong>Methods: </strong>Our research was performed on the basis of National Health and Nutrition Examination Survey (NHANES) database, involving 40,275 participants ranging from 1999 to 2018. The formula of CMI is [waist circumference (cm) / height (cm)] × [triglyceride (mg/dL) / high-density lipoprotein cholesterol (mg/dL)]. Outcome variables consisted of CVD, cancer, and all-cause mortality, which were identified by the International Classification of Diseases (ICD)-10. The correlation between CMI and mortality outcomes was analyzed utilizing the Kaplan-Meier survival modeling, univariate/multivariate Cox regression analysis, smooth curve fitting analysis, threshold effect analysis, and subgroup analysis. Stratification factors for subgroups included age, race/ethnicity, sex, smoking behavior, drinking behavior, BMI, hypertension, and diabetes.</p><p><strong>Results: </strong>The baseline characteristics table includes 4,569 all-cause-induced death cases, 1,113 CVD-induced death cases, and 1,066 cancer-induced death cases. Without adjustment for potential covariates, significantly positive causal correlation existed between CMI and all-cause mortality (HR = 1.03, 95% CI 1.02,1.04, P-value<0.05), CVD mortality (HR = 1.04, 95% CI 1.03, 1.05, P-value<0.05) and cancer mortality(HR = 1.03, 95% CI 1.02, 1.05, P-value<0.05); whereas, after confounding factors were completely adjusted, the relationship lost statistical significance in CMI subgroups (P for trend>0.05). Subgroup analysis found no specific subgroups. Under a fully adjusted model, a threshold effect analysis was performed combined with smooth curve fitting, and the findings suggested an L-shaped nonlinear association within CMI and all-cause mortality (the Inflection point was 0.98); in particular, when the baseline CMI was below 0.98, there existed a negative correlation with all-cause mortality with significance (HR 0.59, 95% CI 0.43, 0.82, P-value<0.05). A nonlinear relation was observed between CMI and CVD mortality. Whereas, the correlation between CMI and cancer mortality was linear.</p><p><strong>Conclusions: </strong>Among the general American population, baseline CMI levels exhibited an L-shaped nonlinear relationship with all-cause mortality, and the threshold value was 0.98. What's more, CMI may become an effective indicator for CVD, cancer, and all-cause mortality prediction. Further investigation is essential to confirm our findings.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"425"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knockdown of RASD1 improves MASLD progression by inhibiting the PI3K/AKT/mTOR pathway.","authors":"Guifang Zeng, Xialei Liu, Zhouying Zheng, Jiali Zhao, Wenfeng Zhuo, Zirui Bai, En Lin, Shanglin Cai, Chaonong Cai, Peiping Li, Baojia Zou, Jian Li","doi":"10.1186/s12944-024-02419-z","DOIUrl":"10.1186/s12944-024-02419-z","url":null,"abstract":"<p><strong>Background: </strong>There is still no reliable therapeutic targets and effective pharmacotherapy for metabolic dysfunction-associated steatotic liver disease (MASLD). RASD1 is short for Ras-related dexamethasone-induced 1, a pivotal factor in various metabolism processes of Human. However, the role of RASD1 remains poorly illustrated in MASLD. Therefore, we designed a study to elucidate how RASD1 could impact on MASLD as well as the mechanisms involved.</p><p><strong>Methods: </strong>The expression level of RASD1 was validated in MASLD. Lipid metabolism and its underlying mechanism were investigated in hepatocytes and mice with either overexpression or knockdown of RASD1.</p><p><strong>Results: </strong>Hepatic RASD1 expression was upregulated in MASLD. Lipid deposition was significantly reduced in RASD1-knockdown hepatocytes and mice, accompanied by a marked downregulation of key genes in the signaling pathway of de novo lipogenesis. Conversely, RASD1 overexpression in hepatocytes had the opposite effect. Mechanistically, RASD1 regulated lipid metabolism in MASLD through the PI3K/AKT/mTOR signaling pathway.</p><p><strong>Conclusions: </strong>We discovered a novel role of RASD1 in MASLD by regulating lipogenesis via the PI3K/AKT/mTOR pathway, thereby identifying a potential treatment target for MASLD.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"23 1","pages":"424"},"PeriodicalIF":3.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}